Innovating Solutions for Unmet Medical Needs
Dedicated to advancing research for innovative therapeutic agents.
Our Mission
Our mission is to translate scientific discovery into safe, effective, and accessible treatments that improve quality of life, reduce suffering, and make a meaningful impact on patients and families around the world.
Our Vision
To develop innovative therapies that address significant unmet medical needs.
USFCR Verified Vendor
Wright Therapeutics is registered with the United States federal government and recognized as a verified vendor through the U.S. Federal Contractor Registration (USFCR) program
Our Goal
Drug Development
Our goal is to create safer, more effective treatments that improve patient outcomes and quality of life through development of novel therapeutic agents designed to address unmet needs.
Allergy
Inflamation
Immune-Mediated
Research
Lead Project
Wright Therapeutics’ current lead program is the development of a novel anti-allergy therapeutic. The project has successfully completed advanced in silico molecular modeling and computational drug design, and the lead compound has been synthesized. The program is now advancing into biological testing to evaluate efficacy, safety, and pharmacologic properties as part of the preclinical development process.
Would you like updates?
Join our contact list to be informed of our progress.
By clicking Sign Up you’re confirming that you agree to receive our releases.
Dr Kenneth Wright, Founder
Building on a career dedicated to improving human health.
Dr. Kenneth W. Wright, founder of Wright Therapeutics, is an internationally recognized physician-scientist, educator, and innovator with more than four decades of experience in medicine, clinical research, and therapeutic development. He has authored over 100 peer-reviewed scientific publications, written leading medical textbooks, and led major multicenter clinical research studies that have helped advance patient care worldwide. Dr. Wright has been awarded a National Institute of Health grant as Principle Investigator and Study Chair for “Early Surgery for Congenital Esotropia Trial” (EY12107).